Solinasine Succinate API

Name	Solinasine Succinate
Chinese name	琥珀酸索利那新
Cas Number	242478-38-2
Source	India
Qualifications	USDMF/-/-/-/-

Solinasine succinate was developed by Astellas Pharmaceutical Co., Ltd. of Japan, and was approved by the US FDA on November 19, 2004. It is a new generation of M3 receptor antagonist that acts on the M receptor on the detrusor muscle. , To reduce the excessive activity of the detrusor muscle, thereby alleviating the symptoms of urinary urgency, frequent urination and urge incontinence caused by overactive bladder muscles. Compared with similar drugs, it has the highest selectivity for the bladder, so it has a stronger curative effect and better tolerance and compliance for patients. It is formulated by the International Association of Urological Control ICS, the Chinese Medical Association Urology Branch, and the Japanese Urological Society The first-line treatment recommended in the guidelines for the treatment of overactive bladder. Solinasine succinate has a lower risk of adverse reactions than tolterodine, especially the most common adverse reaction is dry mouth, and its safety is better than tolterodine. According to the terminal sales data of China's public medical institutions in 2019, the sales of Solina Succinate Tablets are around 63 million yuan.

Hot Tags: solinasine succinate api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Escitalopram Oxalate API, Lapatinib Ditosylate API, Fulvestrant API, Bosentan API, Lercanidipine Hydrochloride API, Salmeterol Xinafoate API

• Previous: Bemeprost API
• Next: Bosentan API